NCT00372515已完成1 期
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
David M. Jackman, MD2 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- To assess the safety of administering gefitinib in doses of 750mg to 1250mg in adult patients with carcinomatous meningitis from non-small cell lung cancer with known or suspected somatic EGFR mutations.
研究概览
简要总结
The primary purposes of this study are to find out if using high doses of the drug Gefitinib (Iressa) as a way to treat patients with non-small cell lung cancer that has spread to the covering of the brain and/or spinal cord (meninges) results in any bad side effects; and to determine the highest dose that can be given to patients in this setting.
详细描述
- The standard therapy for this type of cancer is to give chemotherapy directly into the spinal fluid, usually by a spinal tap. Some chemotherapy may, in some cases, be combined with radiation. This study looks at a different way of treating this type of cancer.
- This study is specifically for patients whose lung cancer has changes in a protein called the epidermal growth factor receptor (EGFR). The study drug, gefitinib, was developed to stop the signals from the EGFR that tell certain types of lung cancers tumors to grow. By using higher doses than are normally used, we hope to increase the amount of drug in the spinal fluid to attempt to kill the cancer cells around the spinal cord and brain.
- Since we are looking for the highest dose of gefitinib that can be given safely, not everyone who participates in this study will be receiving the same amount of drug.
- Patients will start taking gefitinib daily by mouth on Day 1 and will continue taking this medication daily at home. On the first day the patient takes gefitinib and on Day 14 of each treatment cycle (1 cycle equals 28 days), the patient will undergo: Physical examination by the study doctor and a detailed neurological exam by a neuro-oncologist; sampling of cerebrospinal fluid (CSF) by lumbar puncture; review of current medications; measurement of vital signs; check on the patients ability to perform daily activities; blood work.
- If the patient is tolerating the study medication well, then the patient will receive a lower dose for days 15-28 of the cycle.
- At the end of each cycle on Day 28, the patient will meet with the study doctor and have the following: a physical examination; review of current medications; measurement of vital signs, check on the patients ability to perform daily activities; blood tests; MRI of the brain and spinal cord to assess tumor response; every two cycles a CT scan of the chest and abdomen to assess the tumor response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of non-small cell lung cancer of any histologic subtype
- •High likelihood of gefitinib sensitivity, as evidenced by one or more of the following: previous complete or partial response to treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor, erlotinib, or gefitinib; known somatic mutation of the EGFR tyrosine kinase
- •Recurrent or persistent disease as manifested by carcinomatous meningitis
- •ECOG PS 0-3
- •Age 18 years or older
- •Greater than 2 weeks since prior radiation therapy
- •Greater than 3 weeks since prior major surgery
- •Adequate hematologic, renal, and/or hepatic function
- •Coagulation parameters: international normalized ratio(INR)less than or equal to 1.5 and an activated thromboplastin time < 50 seconds
排除标准
- •Previous Grade 4 toxicity on gefitinib or erlotinib leading to dose reduction or interruption
- •Uncontrolled brain metastases, or brain metastases associated with mass effect that would contraindicate lumbar puncture
- •Any other malignancy within the past five years, except for adequately treated carcinoma of the cervix, basal or squamous cell carcinomas of the skin
- •Dysphagia
- •Active gastrointestinal disease or disorder that alters gastrointestinal motility or absorption
- •Incomplete healing from previous oncologic or other major surgery
- •Any pre-existing severe or unstable medical condition
- •Any condition requiring concurrent and ongoing use of anticoagulation
- •Inability to undergo collection of CSF, either by repeated lumbar puncture or placement of an Omaya reservoir
- •Pregnant or breastfeeding
- •Concurrent intrathecal drug administration or radiotherapy
- •Concurrent systemic chemotherapy or investigational agent
- •Anticoagulant except aspirin or heparin flushes
- •Enzyme-inducing anti-epileptic drug
- •CYP3A4 inhibitors
研究组 & 干预措施
High dose gefitinib
Experimental
干预措施: Gefitinib (Drug)
结局指标
主要结局
To assess the safety of administering gefitinib in doses of 750mg to 1250mg in adult patients with carcinomatous meningitis from non-small cell lung cancer with known or suspected somatic EGFR mutations.
时间窗: 2 years
次要结局
- To measure the cytologic response rate, response duration, time to neurologic progression, and survival following high dose gefitinib therapy administered on this schedule(2 years)
- to measure gefitinib levels with serum and cerebrospinal fluid while on therapy, and to correlate these levels with toxicity, response and survival(2 years)
- to examine archived tumors for the presence or absence of EGFR mutations and resistance mutations, and to correlate those mutations with cytologic response, time to neurologic progression, and survival.(2 years)
研究者
David M. Jackman, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaMyelogenous Leukemia, AcuteNCT00130702Dana-Farber Cancer Institute18
已完成
1 期
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid TumorsSolid TumorsNCT00186979St. Jude Children's Research Hospital34
已完成
3 期
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never SmokerLung CancerNCT00455936National Cancer Center, Korea315
已完成
2 期
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryNon-small Cell Lung CancerNCT02804776National Cancer Centre, Singapore15
已完成
2 期
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA PatientsFriedreich AtaxiaNCT02035020Azienda Policlinico Umberto I10